期刊
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
卷 23, 期 12, 页码 3662-3666出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmcl.2013.02.083
关键词
TAK-960; PLK1 inhibitor; Structure-based drug design; Antitumor activity; Multidrug resistance
Using structure-based drug design, we identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960. TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies. (C) 2013 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据